SAGCEM.NSE

Sagar Cements Ltd.

The project will substitute fossil fuels with biomass-derived syngas to provide heat for cement manufacturing.

In this briefing: The Beat Ideas: Dharmaj Crop Guard - From Capex Drag to Operating Leverage Propellant Primer: SG Mart (SGMART IN) - Nov 2025 APAC Healthcare Weekly (November 16) – Leads Bio, Henlius Bio, Otsuka, ABL Bio, Boryung, Eubiologics Why Biocon's Merger Is the Cleaner, Cheaper Path to Value Unlock? Primer: Sagar Cements (SGC IN) - Nov 2025 1. The Beat Ideas: Dharmaj Crop Guard - From Capex Drag to Operating Leverage Propellant Dharmaj Crop Guard had commissioned its INR 275 crore Active Ingredients (AI) plant, cementing its transformation from a formulations-only company to a fully integrated AgroChem player. This strategic backward integration provides a massive new growth lever . However, it came at a short-term cost, as "front-loaded expenses " resulting in EBITDA losses from new plant last year. With the new plant's losses absorbed, Dharmaj is positioned to leverage its integrated model , a pan-India distribution network, to pursue its ambition of becoming a 2,000 crore company by 2030. 2.

In this briefing: Primer: SG Mart (SGMART IN) - Nov 2025 APAC Healthcare Weekly (November 16) – Leads Bio, Henlius Bio, Otsuka, ABL Bio, Boryung, Eubiologics Why Biocon's Merger Is the Cleaner, Cheaper Path to Value Unlock? Primer: Sagar Cements (SGC IN) - Nov 2025 Primer: Olectra Greentech (OLECTRA IN) - Nov 2025 1. Primer: SG Mart (SGMART IN) - Nov 2025 SG Mart is rapidly expanding its B2B marketplace for building materials, primarily focusing on steel, with an aggressive growth strategy aiming to capture a significant share of the large and fragmented Indian market. The company benefits from the strong backing of the APL Apollo Group, providing it with industry relationships, funding, and brand leverage for its B2C distribution. Key risks include the highly competitive nature of the steel trading industry, which operates on thin margins, and the volatility of steel prices, which can impact profitability. This content is AI-generated and displayed for general informational purposes only.

In this briefing: APAC Healthcare Weekly (November 16) – Leads Bio, Henlius Bio, Otsuka, ABL Bio, Boryung, Eubiologics Why Biocon's Merger Is the Cleaner, Cheaper Path to Value Unlock? Primer: Sagar Cements (SGC IN) - Nov 2025 Primer: Olectra Greentech (OLECTRA IN) - Nov 2025 The Beat Ideas: DISA India - Engineering the Next Decade of Indian Foundries 1. APAC Healthcare Weekly (November 16) – Leads Bio, Henlius Bio, Otsuka, ABL Bio, Boryung, Eubiologics Leads Biolabs initiated Phase 2 clinical study evaluating LBL-024 for the first-line treatment of HCC. Henlius Biotech got FDA approval for Poherdy, as the first interchangeable biosimilar to Roche’s Perjeta. Otsuka announced positive Phase 3 interim analysis of sibeprenlimab for immunoglobulin A nephropathy. ABL Bio signed technology transfer and joint R&D agreement with Eli Lilly for upfront payment of $40M. Boryung Pharmaceutical began construction to double its oral penicillin production capacity. Eubiologics published positive result from Phase 3 clinical trial evaluating EuTYPH-C, a typhoid conjugate vaccine. 2.